These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 23506904)
1. Transporter biology in drug approval: regulatory aspects. Maeda K; Sugiyama Y Mol Aspects Med; 2013; 34(2-3):711-8. PubMed ID: 23506904 [TBL] [Abstract][Full Text] [Related]
2. Anderson LL; Etchart MG; MacNair L; Land MH; Mosesova IA; Bonn-Miller MO; Arnold JC Cannabis Cannabinoid Res; 2022 Jun; 7(3):304-317. PubMed ID: 33998860 [No Abstract] [Full Text] [Related]
3. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models. Varma MV; El-Kattan AF J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery. Feng B; Varma MV; Costales C; Zhang H; Tremaine L Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Vermeer LM; Isringhausen CD; Ogilvie BW; Buckley DB Drug Metab Dispos; 2016 Mar; 44(3):453-9. PubMed ID: 26668209 [TBL] [Abstract][Full Text] [Related]
6. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved. Li R; Barton HA; Varma MV Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496 [TBL] [Abstract][Full Text] [Related]
7. Role of Hepatic Drug Transporters in Drug Development. Liu H; Sahi J J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168 [TBL] [Abstract][Full Text] [Related]
8. Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System. El-Kattan AF; Varma MVS Drug Metab Dispos; 2018 May; 46(5):729-739. PubMed ID: 29496721 [TBL] [Abstract][Full Text] [Related]
9. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Yoshida K; Maeda K; Sugiyama Y Annu Rev Pharmacol Toxicol; 2013; 53():581-612. PubMed ID: 23140240 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps. Okudaira N J Pharm Sci; 2017 Sep; 106(9):2251-2256. PubMed ID: 28533120 [TBL] [Abstract][Full Text] [Related]
11. Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Yoshida K; Maeda K; Sugiyama Y Clin Pharmacol Ther; 2012 Jun; 91(6):1053-64. PubMed ID: 22534868 [TBL] [Abstract][Full Text] [Related]
12. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Soars MG; Webborn PJ; Riley RJ Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709 [TBL] [Abstract][Full Text] [Related]
13. The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates. Perri D; Ito S; Rowsell V; Shear NH Can J Clin Pharmacol; 2003; 10(1):17-23. PubMed ID: 12687033 [TBL] [Abstract][Full Text] [Related]
14. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo. Poirier A; Cascais AC; Bader U; Portmann R; Brun ME; Walter I; Hillebrecht A; Ullah M; Funk C Drug Metab Dispos; 2014 Sep; 42(9):1411-22. PubMed ID: 24939652 [TBL] [Abstract][Full Text] [Related]
15. Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group. Rollison HE; Mitra P; Chanteux H; Fang Z; Liang X; Park SH; Costales C; Hanna I; Thakkar N; Vergis JM; Bow DAJ; Hillgren KM; Brumm J; Chu X; Hop CECA; Lai Y; Li CY; Mahar KM; Salphati L; Sane R; Shen H; Taskar K; Taub M; Tohyama K; Xu C; Fenner KS Drug Metab Dispos; 2024 Jun; 52(7):582-596. PubMed ID: 38697852 [TBL] [Abstract][Full Text] [Related]
16. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Nies AT; Koepsell H; Damme K; Schwab M Handb Exp Pharmacol; 2011; (201):105-67. PubMed ID: 21103969 [TBL] [Abstract][Full Text] [Related]
17. A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters. Tátrai P; Schweigler P; Poller B; Domange N; de Wilde R; Hanna I; Gáborik Z; Huth F Drug Metab Dispos; 2019 Jul; 47(7):768-778. PubMed ID: 31068368 [TBL] [Abstract][Full Text] [Related]
18. Membrane transporters in drug development. Keogh JP Adv Pharmacol; 2012; 63():1-42. PubMed ID: 22776638 [TBL] [Abstract][Full Text] [Related]
19. Drug trafficking: recent advances in therapeutics and disease. Sprowl JA; Sparreboom A Clin Pharmacol Ther; 2012 Nov; 92(5):531-4. PubMed ID: 23085872 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of drug transporters in the enterohepatic circulation. Stieger B; Meier PJ Pharmacogenomics; 2011 May; 12(5):611-31. PubMed ID: 21619426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]